blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP4104865

EP4104865 - ANTI-EGFR ANTIBODY DRUG CONJUGATES [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  20.10.2023
Database last updated on 29.06.2024
FormerRequest for examination was made
Status updated on  23.06.2023
FormerThe application has been published
Status updated on  18.11.2022
Most recent event   Tooltip23.04.2024Deletion: Reply to examination report 
23.04.2024New entry: Reply to examination report 
Applicant(s)For all designated states
AbbVie Inc.
1 North Waukegan Road
North Chicago, IL 60064 / US
[2022/51]
Inventor(s)01 / BOGHAERT, Erwin R.
Pleasant Prairie, 53158 / US
02 / SOUERS, Andrew J.
Libertyville, 60048 / US
03 / PHILLIPS, Andrew C.
Libertyville, 60048 / US
04 / JUDD, Andrew S.
Grayslake, 60030 / US
05 / BRUNCKO, Milan
Green Oaks, 60048 / US
 [2022/51]
Representative(s)Schlich, George, et al
Schlich
9 St Catherine's Road
Littlehampton, West Sussex BN17 5HS / GB
[2022/51]
Application number, filing date22166591.207.06.2017
[2022/51]
Priority number, dateUS201662347416P08.06.2016         Original published format: US 201662347416 P
[2022/51]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP4104865
Date:21.12.2022
Language:EN
[2022/51]
Search report(s)(Supplementary) European search report - dispatched on:EP22.11.2022
ClassificationIPC:A61K47/68, C07K16/28, A61K39/395, A61K39/00, A61P35/00, A61P43/00
[2022/51]
CPC:
A61K39/39591 (EP,CN,IL,KR); A61K47/6803 (EP,CN,IL,KR,US); C07K16/2863 (EP,CN,IL,KR,US);
A61K31/4439 (CN,IL); A61K31/47 (CN,IL); A61K31/4985 (CN,IL);
A61K38/04 (CN,IL); A61K45/06 (CN,IL,US); A61K47/6849 (EP,CN,IL,KR,US);
A61K47/6889 (EP,IL); A61P35/00 (EP,CN,IL,KR,US); A61P43/00 (EP,CN,IL);
A61K2039/505 (EP,IL,KR); C07K2317/51 (CN,IL); C07K2317/515 (CN,IL);
C07K2317/56 (CN,IL); C07K2317/565 (CN,IL); C07K2317/73 (EP,CN,IL,KR) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/30]
Former [2022/51]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
Extension statesBANot yet paid
MENot yet paid
TitleGerman:ANTI-EGFR-ANTIKÖRPER-WIRKSTOFF-KONJUGATE[2022/51]
English:ANTI-EGFR ANTIBODY DRUG CONJUGATES[2022/51]
French:CONJUGUÉS DE MÉDICAMENTS-ANTICORPS ANTI-EGFR[2022/51]
Examination procedure21.06.2023Amendment by applicant (claims and/or description)
21.06.2023Examination requested  [2023/30]
21.06.2023Date on which the examining division has become responsible
23.10.2023Despatch of a communication from the examining division (Time limit: M06)
23.04.2024Reply to a communication from the examining division
Parent application(s)   TooltipEP17731394.7  / EP3468996
Fees paidRenewal fee
04.04.2022Renewal fee patent year 03
04.04.2022Renewal fee patent year 04
04.04.2022Renewal fee patent year 05
04.04.2022Renewal fee patent year 06
31.03.2023Renewal fee patent year 07
31.03.2024Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]WO2013055897  (ABBVIE INC [US]);
 [A]WO2015143382  (ABBVIE INC [US]);
 [AP]WO2016094505  (ABBVIE INC [US]);
 [AP]WO2016094509  (ABBVIE INC [US]);
 [AP]WO2016094517  (ABBVIE INC [US])
by applicantWO8912624
 WO9005144
 US5124471
 US5286850
 US5434287
 US5624821
 US5648260
 US5714350
 WO9954342
 EP1176195
 US6350861
 US2002137134
 WO03016466
 WO03035835
 US2004018590
 WO2004010957
 WO2005100584
 US2005271615
 US2006116422
 US7223837
 US2009318668
 US2010152725
 US7989434
 US2012183471
 US8349308
 US8399512
 US2013224228
 US8524214
 US8535678
 US8568728
 US2013309256
 WO2013173337
 WO2014093379
 WO2014093394
 WO2014093640
 US2015337042
 US9493568
 US2016339117
 US20130189218
 US20140017265
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.